Search Results - "Atiya, Bilal"

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study by Murage, Mwangi J., Princic, Nicole, Park, Julie, Malatestinic, William, Zhu, Baojin, Atiya, Bilal, Kern, Scott A., Stenger, Keri B., Sprabery, Aubrey Trevelin, Ogdie, Alexis

“…Objective To describe adherence, persistence, discontinuation, restarting, switching, dosing, and health care costs among patients with psoriatic arthritis…”
Get full text

Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings by Blauvelt, Andrew, Shi, Nianwen, Somani, Najwa, Burge, Russel, Zhu, Baojin, Ridenour, Terri L., Lew, Carolyn R., Zimmerman, Nicole M., Atiya, Bilal, Murage, Mwangi J.

“…Real-world data on long-term treatment patterns associated with interleukin-17A inhibitors in plaque psoriasis are lacking. To compare ixekizumab or…”
Get full text

26718 Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients by Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Ridenour, Terri L., Somani, Najwa, Zhu, Baojin, Atiya, Bilal, Lew, Carolyn R., Kern, Scott A., Zimmerman, Nicole M., Murage, Mwangi J.

Get full text

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry by Lockshin, Benjamin, Cronin, Angel, Harrison, Ryan W., McLean, Robert R., Anatale‐Tardiff, Laura, Burge, Russel, Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Gallo, Gaia, Strober, Bruce, Van Voorhees, Abby

“…To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors (TNFi) among patients with psoriasis (PsO) in a real‐world…”
Get full text

Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs by Murage, Mwangi J, Princic, Nicole, Park, Julie, Malatestinic, William N, Zhu, Baojin, Atiya, Bilal, Kern, Scott A, Stenger, Keri B, Sprabery, Aubrey Trevelin, Ogdie, Alexis

“…Biologic and targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies are used in management of psoriatic arthritis (PsA). Although previous…”
Get full text

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months by Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Somani, Najwa, Ridenour, Terri L., Zhu, Baojin, Atiya, Bilal, Lew, Carolyn R., Zimmerman, Nicole M., Murage, Mwangi J.

“…Introduction Real-world data comparing effectiveness of ixekizumab (IXE) and secukinumab (SEC) among biologic-experienced patients are limited. This study…”
Get full text

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry by Lockshin, Benjamin, Harrison, Ryan W., McLean, Robert R., Crabtree, Margaux M., Konicek, Bruce W., Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Burge, Russel T.

“…Introduction The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and…”
Get full text

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months by Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Atiya, Bilal, Zhu, Baojin, Somani, Najwa, Ridenour, Terri, Lew, Carolyn R., Zimmerman, Nicole M., Murage, Mwangi J.

“…Objective The aim of this study was to compare healthcare costs between ixekizumab (IXE)-treated and secukinumab (SEC)-treated patients with psoriasis over a…”
Get full text